At a glance
ClinicalIndex Comparison Record- ✓Age 20-79 years at informed consent
- ✓Unresectable adenocarcinoma of the large intestine (excluding appendix and anal canal)
- ✓Measurable or evaluable lesion(s) per RECIST v1.1 (not essential)
- ✓No prior chemotherapy for colorectal cancer, except adjuvant fluoropyrimidine >24 weeks prior (no oxaliplatin)
- ✕Known or strongly suspected brain metastasis
- ✕Synchronous or metachronous cancers with disease-free period ≤5 years (excluding colorectal cancer and certain mucosal cancers)
- ✕Body cavity fluid requiring treatment (pleural effusion, ascites, pericardial effusion)
- ✕Radiotherapy within 4 weeks prior to enrollment (except pain relief for bone metastases)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer
In Brief
A Phase 3 clinical trial evaluating oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab and oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab for Colorectal Cancer. Completed, enrolled 823 participants across 155 sites.
Detailed Summary
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer.
Study Details
Timeline
Interventions
oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion